SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder

American Journal of Psychiatry

Volumn 159, Issue 12, 2002, Pages 2048-2054

  Rinne, Thomas ^a,b   Van den Brink, Wim ^a,b   Wouters, Luuk ^a,b   Van Dyck, Richard ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSION; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; IMPULSIVENESS; MENTAL INSTABILITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BORDERLINE PERSONALITY DISORDER; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUVOXAMINE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PATIENT DROPOUTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036895623     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.12.2048     Document Type: Article

References (30)

1. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK: Aggression, suicide, and serotonin: Relationships to CSF amine metabolites. Am J Psychiatry 1982; 139:741-746
2. Coccaro EF: Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989; 155:52-62
3. Oquendo MA, Mann JJ: The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23:11-25
4. Norden M: Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:885-893
5. Cornelius J, Soloff PH, Perel J, Ulrich RF: Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151-154
6. Coccaro EF, Astill JL, Herbert JL, Schut A: Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol 1990; 10:373-375
7. Cornelius J, Soloff PH, Perel J, Ulrich RF: A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991; 11:116-120
8. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064-1067
9. Coccaro EF, Kavoussi RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54:1081-1088
10. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23-29
11. Coccaro EF, Siever L, Klar HM, Maurer G: Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989; 46:587-599
12. Soloff PH: Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62:195-214
13. Soloff PH: Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23:169-192
14. American Psychiatric Association: Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001; 158(Oct suppl)
15. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha A, Levin A, Reynolds V: Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998; 155:1733-1739
16. Kent JM, Coplan JD, Gorman JM: Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998; 44:812-824
17. Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE Jr, Carter WP, Mitchell JE, Strakowski SM, Pope HG Jr, Coleman BS, Jonas JM: Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998; 155:1756-1762
18. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of post-traumatic stress disorder: A randomized controlled trial. JAMA 2000; 283:1837-1844
19. Schotte CKW, De Doncker D, Vankerckhoven C, Vertommen H, Cosyns P: Self-report assessment of the DSM-IV personality disorders: Measurement of trait and distress characteristics: The ADP-IV. Psychol Med 1998; 28:1179-1188
20. Pfohl B, Blum N, Zimmerman M: Structured Interview for DSM-IV Personality: SIDP-IV. Iowa City, University of Iowa, Department of Psychiatry, 1995
21. Jong de CAJ, Derks FCH, Oel van C, Rinne T: Authorized Dutch Translation of the Structured Interview for DSM-IV Personality Disorders (SIDP-VI). Eindhoven, the Netherlands, Stichting Verslavingszorg Oost Brabant, 1996
22. Arntz A, Hoorn van den M, Cornelis J, Verheul R, Bosch van den W, Bie de AJHT: Reliability and validity of the Borderline Personality Disorder Severity Index. J Personal Disord (in press)
23. Weaver TL, Clum GA: Early family environments and traumatic experiences associated with borderline personality disorder. J Consult Clin Psychol 1993; 61:1068-1075
24. World Health Organization: Composite International Diagnostic Interview (CIDI), Version 2.1. Geneva, Switzerland, WHO, 1997
25. Smitten ter MH, Smeets RMW, Brink van den W: Composite International Diagnostic Interview, Core Version 2.1 (Dutch Translation). Amsterdam, University of Amsterdam, Academic Medical Center, WHO-CIDI Training and Reference Center, 1997
26. Dixon WJ (ed): BMDP Statistical Software Manual, vol 2. Berkeley, University of California Press, 1992
27. Verhoeven W, Tuinier S: Biological and psychopharmacological aspects of impulse-control disorders. Acta Neuropsychiatrica 1997; 9:89-93
28. Cleare AJ, Bond AJ: Does central serotonergic function correlate inversely with aggression? A study using D-fenfluramine in healthy subjects. Psychiatry Res 1997; 69:89-95
29. Manuck SB, Flory JD, McCaffery JM, Matthews KA, Mann JJ, Muldoon MF: Aggression, impulsivity, and central nervous system serotonergic responsivity in a nonpatient sample. Neuropsychopharmacology 1998; 19:287-299
30. Rinne T, Westenberg HGM, Den Boer JA, Brink van den W: Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry 2000; 47:548-556